Suchergebnisse - "Tu, Meifeng"

PubPharm (61)

1

Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma : a phase II trial

enthalten in: BMC medicine | 2024

von Liu, Y. | Ping, L. | Song, Y. | +11

2

Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial

enthalten in: BMC medicine | 2024

von Liu, Y. | Ping, L. | Song, Y. | +11

3

Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin's lymphoma : 2-year results of a phase 1 trial

enthalten in: Bone marrow transplantation | 2023

von Ying, Z. | Xie, Y. | Zheng, W. | +16

4

A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma

enthalten in: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu | 2022

von Ying, Z. | He, T. | Jin, S. | +14

5

Primary mediastinal large B cell lymphoma

enthalten in: Thoracic cancer | 2021

von Yu, Y. | Dong, X. | Tu, M. | +1

6

Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies

enthalten in: Journal of hematology & oncology | 2021

von Jiang, B. | Qi, J. | Song, Y. | +7

7

Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies

enthalten in: Journal of hematology & oncology | 2021

von Jiang, B. | Qi, J. | Song, Y. | +7

8

Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies

enthalten in: BMC cancer | 2021

von Ying, Z. | He, T. | Wang, X. | +18

9

Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies

enthalten in: BMC cancer | 2021

von Ying, Z. | He, T. | Wang, X. | +18

10

Primary mediastinal large B cell lymphoma

enthalten in: Thoracic Cancer | 2021

von Yu, Y. | Dong, X. | Tu, M. | +1

1
2
3
4
5
6
7
Nächster »
[7]